Evidence map›Paper›PMID 21805084›Full record

ArticleInternational urology and nephrology2012

Outcome of deceased donor renal transplantation in diabetic nephropathy: a single-center experience from a developing country.

Vivek B Kute, Suraj M Godara, Pankaj R Shah, Siddharth H Jain, D P Engineer, Himanshu V Patel, Manoj R Gumber, Bipin C Munjappa, V V Sainaresh, Aruna V Vanikar and 3 more

Abstract read
PubMed Publisher
In one paragraph

Article in International urology and nephrology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.1field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 1 institution in 1 country.

Vivek B KuteDepartment of Nephrology and Clinical Transplantation, Institute of Kidney Diseases and Research Center and Dr. H L Trivedi Institute of Transplantation Sciences, Civil Hospital Campus, Asarwa, Ahmadabad 380016, Gujarat, India. drvivekkute@rediffmail.com
Suraj M Godara
Pankaj R Shah
Siddharth H Jain
D P Engineer
Himanshu V Patel
Manoj R Gumber
Bipin C Munjappa
V V Sainaresh
Aruna V Vanikar
Pranjal R Modi
Veena R Shah
Hargovind L Trivedi
Institute of Transplantation Sciences · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundType 2 diabetes mellitus (DM) is the commonest cause of end-stage renal disease (ESRD) worldwide. Renal transplantation (RTx) is the best therapeutic modality for such patients. First-degree relatives of patients with type 2 DM have high risk of diabetes/pre-diabetes. Parents are often too old to be suitable donors, and siblings/children/spouse are either not suitable/acceptable or do not come forward for organ donation. This leaves deceased donation (DD) as only suitable donors. Data scarcity on DDRTx outcome in diabetic nephropathy (DN) prompted us to review our experience. This retrospective single-center 10-year study was undertaken to evaluate patient/graft survival, graft function, rejection episodes, and mortality in these patients. MATERIALS AND

methodsBetween January 2001 and March 2011, thirty-five DN-ESRD patients underwent DDRTx in our center following cardiac fitness assessment of recipients. All patients received single-dose rabbit-anti-thymocyte globulin for induction and steroids, calcineurin inhibitor, and mycophenolate mofetil/azathioprine for maintenance immunosuppression. Mean recipient age was 49.66 ± 6.76 years, and 25 were men. Mean donor age was 50 ± 16.45 years, 23 were men.

resultsOver a mean follow-up of 2.28 ± 2.59 years, patient and graft survival rates were 68.5% and 88.5%, respectively, with mean SCr of 1.9 ± 0.62 mg/dl. Delayed graft function was observed in 34.3% patients, and 25.7% had biopsy-proven acute rejection; 31.5% patients died, mainly because of infections (22.8%), coronary artery disease (2.86%), and cerebrovascular events (5.7%).

conclusionDDRTx in patients with DN has acceptable graft function and patient/graft survival over 10-year follow-up in our center and, therefore, we believe it should be encouraged.

Indexed as

Graft SurvivalAdultAgedAntilymphocyte SerumAzathioprineCadaverCalcineurin InhibitorsCreatinineDelayed Graft FunctionDeveloping CountriesDiabetes Mellitus, Type 2Diabetic NephropathiesFemaleGraft RejectionHumansImmunosuppression TherapyAntilymphocyte SerumAzathioprineCalcineurin InhibitorsCreatinineImmunosuppressive AgentsMycophenolic AcidSteroids

Identifiers

PMID21805084
OpenAlexW2086309158

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.